Leading the cancer vaccine revolution

The challenge: Cancer metastases still cause 70–90% of cancer deaths. Yet cancer vaccines still haven’t become a mainstream treatment option. The cancer vaccine field has been reinvigorated since the COVID-19 pandemic, but solid tumours present different challenges to infectious diseases. How do you select the right targets, with the right vectors, for the right patients, at the right time?


The breakthrough: By drawing on expertise in oncology, immunology, and machine learning, Infinitopes has created its own antigen-discovery technology to identify the best target combinations to treat solid tumours. This technology helped Infinitopes develop its lead asset, the novel cancer vaccine ITOP1, which is due to enter the clinic later this year. The company recently raised £12.8m in an oversubscribed seed funding round.

Our role: Cancer Research Horizons entered into an IP license with the company granting rights to a foundational patent, and subsequently invested in its seed round.